Sareum Holdings plc (LON:SAR – Get Free Report)’s stock price was down 4.3% on Friday . The company traded as low as GBX 21 and last traded at GBX 22. 189,670 shares were traded during trading, a decline of 16% from the average daily volume of 226,365 shares. The stock had previously closed at GBX 23.
Sareum Trading Down 4.3%
The stock’s 50-day moving average price is GBX 21.65 and its 200-day moving average price is GBX 18.32. The company has a market capitalization of £30.48 million, a P/E ratio of -5.64 and a beta of -1.08.
About Sareum
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
See Also
- Five stocks we like better than Sareum
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
